• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: ATRIUM MEDICAL CORPORATION ATRIUM ICAST COVERED STENT; ILIAC COVERED STENT, ARTERIAL

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

ATRIUM MEDICAL CORPORATION ATRIUM ICAST COVERED STENT; ILIAC COVERED STENT, ARTERIAL Back to Search Results
Device Problems Nonstandard Device (1420); Device Dislodged or Dislocated (2923)
Patient Problem Appropriate Clinical Signs, Symptoms, Conditions Term / Code Not Available (4581)
Event Date 07/23/2021
Event Type  Injury  
Event Description
On (b)(6) 2021 routine transluminal angioplasty.Failure of atrium icast sheath: dislodgement of stent.Resulting in "transperitoneal open exposure" of the superior mesenteric artery to retrieve stent.Then retrograde with gore vbx stent.Which occluded after 5 months.On (b)(6) 2022 underwent ilio-mesenteric arterial bypass using graft.Recall # z-1077-2022, event: (b)(6), status: ongoing.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
ATRIUM ICAST COVERED STENT
Type of Device
ILIAC COVERED STENT, ARTERIAL
Manufacturer (Section D)
ATRIUM MEDICAL CORPORATION
MDR Report Key16733003
MDR Text Key313330312
Report NumberMW5116608
Device Sequence Number1
Product Code PRL
Combination Product (y/n)N
Reporter Country CodeUS
Number of Events Reported1
Summary Report (Y/N)N
Report Source Voluntary
Reporter Occupation Unknown
Type of Report Initial
Report Date 04/10/2023
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received04/12/2023
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? Yes
Device Operator Health Professional
Device Expiration Date03/03/2022
Was Device Available for Evaluation? Yes
Patient Sequence Number1
Treatment
ASPIRIN 81 MG; BRILINTA 60 MG; FEROSUL FERROUS SULFATE 65 MG ; ROSUVASTATIN 20 MG
Patient Outcome(s) Required Intervention; Disability; Other; Hospitalization; Life Threatening;
Patient Age63 YR
Patient SexMale
Patient Weight61 KG
Patient EthnicityNon Hispanic
Patient RaceWhite
-
-